ArticleFrontiers in oncology2026
Leptomeningeal metastasis from large-cell neuroendocrine carcinoma of the cervix: a case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leptomeningeal metastasis (LM) from neuroendocrine carcinoma of the cervix (NECC) is extremely rare, with only five cases reported in the literature. Immune checkpoint inhibitors (ICIs) have the standard first-line treatment for metastatic cervical carcinoma and have been reported to improve intracranial response and survival in several types of cancer. A 50-year-old woman initially received pelvic radiation and chemotherapy for cervical cancer. At 1 year later, she complained of left breast, supraclavicular, and retroperitoneal lymph node metastases. She received targeted and adjuvant chemotherapy. At 15 months after diagnosis, she received radiotherapy due to nasopharynx and supraclavicular lymph node metastasis as well as treatment with a bispecific antibody targeting PD-1 and CTLA-4, cadonilimab, combined with chemotherapy. At 20 months after diagnosis, she experienced a transient unconsciousness and severe headache, nausea, and vomiting. The cytological demonstration of malignant cells in the cerebrospinal fluid (CSF) confirmed the presence of leptomeningeal metastasis. The therapeutic regimen then consisted of intrathecal chemotherapy combined with oral temozolomide. The authors highlight the diagnosis and treatment of LM from NECC, providing a rare clinical scenario.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.